We Ran A Stock Scan For Earnings Growth And SonoScape Medical (SZSE:300633) Passed With Ease
We Ran A Stock Scan For Earnings Growth And SonoScape Medical (SZSE:300633) Passed With Ease
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks' without any revenue, let alone profit. Unfortunately, these high risk investments often have little probability of ever paying off, and many investors pay a price to learn their lesson. A loss-making company is yet to prove itself with profit, and eventually the inflow of external capital may dry up.
投资者通常以发现 “下一件大事” 的想法为指导,即使这意味着在没有任何收入的情况下购买 “故事股票”,更不用说获利了。不幸的是,这些高风险投资通常几乎不可能获得回报,许多投资者为吸取教训付出了代价。亏损的公司尚未用利润证明自己,最终外部资本的流入可能会枯竭。
In contrast to all that, many investors prefer to focus on companies like SonoScape Medical (SZSE:300633), which has not only revenues, but also profits. Even if this company is fairly valued by the market, investors would agree that generating consistent profits will continue to provide SonoScape Medical with the means to add long-term value to shareholders.
与此形成鲜明对比的是,许多投资者更愿意关注像SonoScape Medical(深圳证券交易所代码:300633)这样的公司,这些公司不仅有收入,还有利润。即使这家公司受到市场的公平估值,投资者也会同意,创造稳定的利润将继续为SonoScape Medical提供为股东增加长期价值的手段。
See our latest analysis for SonoScape Medical
查看我们对SonoScape Medical的最新分析
How Fast Is SonoScape Medical Growing Its Earnings Per Share?
SonoScape Medical的每股收益增长速度有多快?
SonoScape Medical has undergone a massive growth in earnings per share over the last three years. So much so that this three year growth rate wouldn't be a fair assessment of the company's future. So it would be better to isolate the growth rate over the last year for our analysis. SonoScape Medical's EPS has risen over the last 12 months, growing from CN¥0.84 to CN¥1.03. That's a 23% gain; respectable growth in the broader scheme of things.
在过去三年中,SonoScape Medical的每股收益大幅增长。如此之多,以至于这种三年的增长率并不是对公司未来的公平评估。因此,最好将去年的增长率分开来进行分析。在过去的12个月中,SonoScape Medical的每股收益有所增加,从0.84元人民币增长到1.03元人民币。增长了23%;在更广泛的范围内,增长幅度可观。
Top-line growth is a great indicator that growth is sustainable, and combined with a high earnings before interest and taxation (EBIT) margin, it's a great way for a company to maintain a competitive advantage in the market. The music to the ears of SonoScape Medical shareholders is that EBIT margins have grown from 18% to 21% in the last 12 months and revenues are on an upwards trend as well. Both of which are great metrics to check off for potential growth.
收入增长是可持续增长的重要指标,再加上较高的息税前收益(EBIT)利润率,这是公司保持市场竞争优势的好方法。令SonoScape Medical股东听到的消息是,在过去的12个月中,息税前利润率从18%增长到21%,收入也呈上升趋势。这两个指标都是衡量潜在增长的好指标。
In the chart below, you can see how the company has grown earnings and revenue, over time. Click on the chart to see the exact numbers.
在下图中,您可以看到公司如何随着时间的推移实现收益和收入的增长。点击图表查看确切的数字。
![earnings-and-revenue-history](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240131/0-a74f7dad5a26fdb2359fce6b6dc9f47d-0-0f64cecf19115fdb96416e08e7e13730.png/big)
In investing, as in life, the future matters more than the past. So why not check out this free interactive visualization of SonoScape Medical's forecast profits?
在投资中,就像在生活中一样,未来比过去更重要。那么,为什么不看看这个免费的SonoScape Medical的交互式可视化效果呢? 预测 利润?
Are SonoScape Medical Insiders Aligned With All Shareholders?
SonoScape Medical Insiders 是否与所有股东保持一致?
Seeing insiders owning a large portion of the shares on issue is often a good sign. Their incentives will be aligned with the investors and there's less of a probability in a sudden sell-off that would impact the share price. So we're pleased to report that SonoScape Medical insiders own a meaningful share of the business. To be exact, company insiders hold 55% of the company, so their decisions have a significant impact on their investments. This makes it apparent they will be incentivised to plan for the long term - a positive for shareholders with a sit and hold strategy. CN¥8.7b That level of investment from insiders is nothing to sneeze at.
看到内部人士拥有已发行股票的很大一部分通常是一个好兆头。他们的激励措施将与投资者保持一致,突然抛售影响股价的可能性较小。因此,我们很高兴地向大家报告,SonoScape Medical内部人士拥有该业务的重要份额。确切地说,公司内部人士持有公司55%的股份,因此他们的决定对他们的投资有重大影响。这清楚地表明,他们将受到激励进行长期规划——对于采取坐仓持股策略的股东来说,这是一个积极因素。CN¥87b 内部人士的这种投资水平没什么好打喷嚏的。
Is SonoScape Medical Worth Keeping An Eye On?
SonoScape Medical 值得关注吗?
One important encouraging feature of SonoScape Medical is that it is growing profits. To add an extra spark to the fire, significant insider ownership in the company is another highlight. These two factors are a huge highlight for the company which should be a strong contender your watchlists. Now, you could try to make up your mind on SonoScape Medical by focusing on just these factors, or you could also consider how its price-to-earnings ratio compares to other companies in its industry.
SonoScape Medical的一个重要令人鼓舞的特点是利润不断增长。另一亮点是该公司拥有大量的内部所有权,这为火上浇油。这两个因素对公司来说是一个巨大的亮点,它应该是你的关注清单的有力竞争者。现在,你可以尝试只关注这些因素,在SonoScape Medical上下定决心,或者你可以 也 考虑一下其市盈率与该行业其他公司的比较。
While opting for stocks without growing earnings and absent insider buying can yield results, for investors valuing these key metrics, here is a carefully selected list of companies in CN with promising growth potential and insider confidence.
虽然选择收益不增长且没有内幕买盘的股票可以产生业绩,但对于估值这些关键指标的投资者来说,以下是精心挑选的具有良好增长潜力和内部信心的内地公司名单。
Please note the insider transactions discussed in this article refer to reportable transactions in the relevant jurisdiction.
请注意,本文中讨论的内幕交易是指相关司法管辖区内应报告的交易。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对这篇文章有反馈吗?对内容感到担忧?直接联系我们。 或者,给编辑团队 (at) simplywallst.com 发送电子邮件。
Simply Wall St的这篇文章本质上是笼统的。我们仅使用公正的方法根据历史数据和分析师的预测提供评论,我们的文章无意作为财务建议。它不构成买入或卖出任何股票的建议,也没有考虑到您的目标或财务状况。我们的目标是为您提供由基本数据驱动的长期重点分析。请注意,我们的分析可能不考虑最新的价格敏感型公司公告或定性材料。简而言之,华尔街没有持有任何上述股票的头寸。